Stonehage Fleming Financial Services Holdings Ltd Invests $132.44 Million in Stryker Corporation $SYK

Posted by Stanley Muller on Aug 28th, 2026

Stonehage Fleming Financial Services Holdings Ltd bought a new position in shares of Stryker Corporation (NYSE:SYK – Free Report) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 420,665 shares of the medical technology company’s stock, valued at approximately $132,442,000. Stryker accounts for about 4.5% of Stonehage Fleming Financial Services Holdings Ltd’s portfolio, making the stock its 10th biggest position.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new stake in Stryker during the second quarter worth about $205,000. Marshall Wace LLP raised its position in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC purchased a new position in Stryker during the second quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker in the second quarter valued at approximately $253,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on SYK shares. Canaccord Genuity Group lowered their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a report on Friday, May 1st. BTIG Research decreased their target price on shares of Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st. JPMorgan Chase & Co. lowered their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Needham & Company LLC cut their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Get Our Latest Analysis on SYK

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 50,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dylan Bram Crotty sold 441 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 351,267 shares of company stock worth $118,197,701. Insiders own 4.60% of the company’s stock.

Stryker Trading Down 2.3%

Shares of SYK stock opened at $322.20 on Friday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The company has a market cap of $123.58 billion, a price-to-earnings ratio of 33.39, a PEG ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock has a 50 day simple moving average of $328.64 and a 200-day simple moving average of $331.47.

Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter last year, the company earned $3.13 EPS. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 36.48%.

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.